Related Experiment Video
Updated: Jun 20, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide levels in patients with erythema nodosum leprosum
José Luiz Fernandes Vieira1, Maria do Socorro da Silva Valente
1Laboratório de Toxicologia da Faculdade de Farmacia da Universidade Federal do Pará, Augusto Corrêa Street 01, Belém, Para, Brazil. jvieira@ufpa.br
Abstract:
Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL). In this study, comparisons were made regarding the plasma concentrations of thalidomide in patients with ENL on the course or after leprosy therapy in a prospective clinical trial. Thalidomide concentrations were measured by liquid chromatography on days 1, 3, and 14 of treatment. After 100 mg/d, the thalidomide concentrations ranged from 0.82 to 1.03 and 0.43 to 0.80 microg/mL, on the course or after leprosy therapy, respectively. No differences were observed in thalidomide concentrations between and within the groups. Our results suggested that leprosy multidrug therapy does not seem to affect the plasma concentrations of thalidomide in patients with ENL.
Related Concept Videos
Graves Disease II: Pathophysiology
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Graves' Disease I: Introduction
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug toxicity: Idiosyncratic Reactions
Antiprotozoal Agents